<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Venous malformations</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Venous malformations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Venous malformations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurence M Boon, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Miikka Vikkula, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emmanuel Seront, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2638055529"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Venous malformations (VMs) are the most frequent slow-flow vascular malformations seen in specialized multidisciplinary centers for vascular anomalies [<a href="#rid1">1</a>]. They result from inborn errors in the development of the venous network, leading to dilated and dysfunctional veins that are deficient in smooth muscle cells. Although inherited forms exist, more than 90 percent of VMs occur sporadically. VMs are present at birth and grow proportionally with the child but may become clinically evident later in life. Depending on their location and extension, symptoms are highly variable and include pain, bleeding, disfigurement, and functional impairment, resulting in significant impairment of quality of life, morbidity, and mortality [<a href="#rid2">2</a>].</p><p>This topic will review the pathogenesis, clinical manifestations, diagnosis, and treatment of VMs. Other congenital vascular anomalies and vascular tumors are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5789.html" rel="external">"Vascular lesions in the newborn"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13730.html" rel="external">"Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13726.html" rel="external">"Capillary malformations (port wine birthmarks) and associated syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13735.html" rel="external">"PHACE syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86314.html" rel="external">"Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13727.html" rel="external">"Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)"</a>.)</p><p></p><p class="headingAnchor" id="H4185226653"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>VMs are a rare disorder, but they are the most common vascular malformation seen in specialized centers. Although epidemiologic data are lacking, their incidence has been estimated at 1 in 2000 to 5000 births. There is no sex predilection [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1176539017"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H399098465"><span class="h2">Genetics and inheritance</span><span class="headingEndMark"> — </span>More than 90 percent of VMs occur sporadically and consist of unifocal lesions. Multifocal lesions are seen in patients with the rare, inherited forms that exhibit autosomal dominant transmission, such as cutaneomucosal venous malformation (VMCM; 1 percent of all VMs) and glomuvenous malformation (GVM; 5 percent of all VMs), and also in two exceedingly rare, sporadic forms: multifocal venous malformation (MVM) and blue rubber bleb nevus (BRBN) syndrome (Bean syndrome) [<a href="#rid3">3,4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>TEK</em></strong><strong> </strong>– <em>TEK</em> gene on chromosome 9p encodes the endothelial receptor tyrosine kinase TIE2. Differing gain-of-function variants in <em>TEK</em> can cause all four subtypes of VMs [<a href="#rid5">5-11</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cutaneomucosal venous malformation (VMCM)</strong> – In VMCM, R849W is the most common germline <em>TEK</em> variant. It causes only weak TIE2 hyperphosphorylation and needs a somatic second hit for lesion formation [<a href="#rid6">6,7,9,10</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sporadic venous malformation</strong> – In sporadic VMs, the somatic L914F variant is identified in 60 percent of <em>TEK</em> mutation-positive lesions [<a href="#rid7">7,8</a>]. The L914F variant has not been identified in the germline, suggesting that it may be incompatible with life when present in all cells.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multifocal venous malformation (MVM) and blue rubber bleb nevus (BRBN) syndrome</strong> – In MVM and BRBN syndrome, lesions most often contain double somatic variants in <em>TEK</em> [<a href="#rid5">5</a>]. In MVM, the most common combination is Y897C-R915C, whereas in BRBN syndrome, it is T1105N-T1106P. In MVM, the patient is mosaic for the R915C change, on top of which the Y897C change can be seen in the lesion. In BRBN syndrome, the two variants seem to have occurred at the same time in a "niche," as both are found with equal frequency in various lesions [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>PIK3CA</em></strong><strong> </strong>– Pathogenic variants in the <em>PIK3CA</em> gene, encoding the p110a catalytic subunit of PI3K, cause approximately 20 percent of common VMs and, similar to <em>TEK</em> variants, result in excessive activation of AKT, low levels of PDGF-beta, and disrupted pericyte coverage surrounding endothelial cells [<a href="#rid12">12</a>]. Three "hotspot" variants, E542K and E545K in the helical domain (exon 9) and H1047R in the kinase domain (exon 20), are frequently identified. The exact same variants are frequently seen in human cancers [<a href="#rid13">13</a>]. In contrast with TIE2-mutated VMs, <em>PIK3CA</em>-mutated VMs do not tend to extend to the skin surface [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>GLMN </em></strong><em>– </em>Glomuvenous malformations (GVMs; MIM #138000) are inherited in an autosomal dominant fashion and caused by loss-of-function variants in the glomulin gene <em>GLMN </em>on chromosome 1p21-22. These variants lead to disruption of pericyte differentiation and accumulation of rounded "glomus" cells in lesions [<a href="#rid14">14,15</a>]. Several somatic second hits have been identified in GVMs, the most common of which is acquired uniparental isodisomy, which leads to duplication of the inherited mutant allele and loss of the wild-type allele in affected tissues [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>KRIT1 </em></strong>– Nodular VMs presenting as a group of small, bell-shaped VMs, especially on the face, may be associated with cerebral cavernous malformations of the brain, caused by germline variants in the cerebral cavernous malformation 1 (<em>CCM1</em>) gene, also called <em>KRIT1</em> [<a href="#rid17">17-20</a>]. (See  <a class="medical medical_review" href="/z/d/html/1087.html" rel="external">"Brain arteriovenous malformations"</a> and  <a class="medical medical_review" href="/z/d/html/1129.html" rel="external">"Vascular malformations of the central nervous system", section on 'Cavernous malformations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>IDH1</em></strong><strong> and </strong><strong><em>IDH2 </em></strong>– Maffucci syndrome, which is characterized by multiple enchondromas and multiple subcutaneous vascular lesions (spindle cell hemangiomas) that may clinically mimic venous anomalies, is caused by somatic variants in the isocitrate dehydrogenase genes <em>IDH1</em> and <em>IDH2 </em>[<a href="#rid21">21</a>]<em>. </em>Maffucci syndrome is also associated with a high risk of chondrosarcoma and other cancers [<a href="#rid21">21-23</a>].</p><p></p><p class="headingAnchor" id="H868576785"><span class="h2">Signaling pathways</span><span class="headingEndMark"> — </span>The mutated TIE2 proteins result in a sustained and ligand-independent activation of the TIE2 receptor and subsequent sustained hyperphosphorylation of AKT, even in confluent cells [<a href="#rid24">24</a>]. The AKT-mediated inhibition of FOXO1 leads to inappropriately low platelet-derived growth factor-beta (PDGF-beta) levels and defective and sparse pericyte coverage [<a href="#rid24">24</a>].</p><p>The tyrosine kinase receptor TIE2, located on endothelial cells, and its ligand angiopoietin-1 (ANG-1), secreted by vascular smooth muscle cells (or pericytes), play a major role in the maturation and stability of veins [<a href="#rid25">25-27</a>]. Knockout of TIE2 or ANG-1 in mice results in impaired blood vessel branching and deficient pericyte coverage [<a href="#rid28">28</a>]. The other ligand, angiopoietin-2 (ANG-2), which is produced by the endothelial cells, seems to be a context-dependent inhibitor of ANG-1 effects, demonstrating tight control of this signaling pathway in endothelial-smooth muscle cell cross-talk.</p><p>Binding of ANG-1 to TIE2 activates the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) signaling pathway, an important pathway implicated in multiple cellular processes, such as protein synthesis, metabolism, and survival [<a href="#rid29">29</a>]. mTOR exists as two complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Activated PI3K phosphorylates AKT on threonine 308, leading to partial activation of AKT. Full activation of AKT requires a second phosphorylation that is induced by mTORC2 [<a href="#rid30">30</a>]. AKT is thereby able to regulate positively the transcription factor STAT-1 and negatively the transcription factor forkhead box protein O1 (FOXO1). The latter results in decreased levels of pericyte attractant platelet-derived growth factor-beta (PDGF-beta). Cell confluence influences PDGF-beta production, in that AKT activity is elevated in sparse endothelial cells and diminishes with confluence, inversely correlating with PDGF-beta production. This implies that normal endothelial cells, when in cell-cell contact upon tube formation, secrete PDGF-beta in order to recruit pericytes [<a href="#rid24">24,31,32</a>]. </p><p class="headingAnchor" id="H404044268"><span class="h2">Animal models</span><span class="headingEndMark"> — </span>The identification of mutation in the TIE2-PI3K-AKT-mTOR pathway led to the development of the first murine model of VMs; mice injected with TIE2-L914F-mutated human umbilical vein endothelial cells developed VMs histologically similar to those of patients with VMs [<a href="#rid33">33</a>]. In these mice, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> decreased the proliferation of endothelial cells and inhibited the excessive activation of AKT, which is responsible for smooth muscle deficiency [<a href="#rid33">33</a>]. Sirolimus was also shown to facilitate the nuclear localization of FOXO1 and the expression of platelet-derived growth factor-beta (PDGF-beta) in mutant endothelial cells, improving paracrine interactions between endothelial cells and smooth muscle cells [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H3365698870"><span class="h2">Vascular changes</span><span class="headingEndMark"> — </span>VMs are slow-flow vascular malformations composed of a network of veins with continuous endothelial lining surrounded by sparse, irregularly distributed vascular smooth muscle cells (pericytes); these vessels are thin-walled, dilated, ectatic, and dysfunctional [<a href="#rid6">6</a>]. Glomuvenous malformations (GVMs) are characterized by the presence of undifferentiated pericytes (glomus cells) surrounding convoluted venous channels [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1523825068"><span class="h2">Coagulation abnormalities</span><span class="headingEndMark"> — </span>The slow flow of blood through the dilated and ectatic vessels results in blood stagnation, activation of the coagulation cascade, thrombus formation, and thrombolysis. This coagulation disorder, called localized intravascular coagulopathy, occurs in approximately 42 percent of patients with VMs [<a href="#rid35">35-39</a>]. </p><p class="headingAnchor" id="H3736722665"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H3530586985"><span class="h2">Common features</span><span class="headingEndMark"> — </span>VMs develop primarily in cutaneous, subcutaneous, or mucosal tissues, but they can affect any tissue or organ, including muscles, joints, viscera, and the central nervous system. (See  <a class="medical medical_review" href="/z/d/html/1129.html" rel="external">"Vascular malformations of the central nervous system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age at presentation </strong>– VMs are usually present at birth, grow with the child, and slowly expand over time. Hormonal changes and puberty can exacerbate the growth. Some VMs, particularly those with predominant intramuscular localization, may become evident only later in life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Site of involvement</strong> – Approximately 40 percent of VMs occur on the extremities, 20 percent on the trunk, and 40 percent on the cervicofacial area [<a href="#rid40">40</a>]. The vast majority are unifocal; only 1 percent are multifocal, with multiple cutaneous and visceral lesions. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lesion appearance</strong> – VMs typically manifest as a light to dark blue skin discoloration overlying a soft, compressible, subcutaneous mass  (<a class="graphic graphic_picture graphicRef105862" href="/z/d/graphic/105862.html" rel="external">picture 1</a>). However, the clinical presentation may be highly variable, depending upon the size, location, and mass effect of the lesion on the adjacent organs. Cervicofacial VMs may lead to physical distortion, facial asymmetry, exophthalmos, or dental disorganization. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated symptoms</strong> – Symptoms are usually absent at birth but appear during childhood, become more severe as the child grows (depending upon the size and location of the malformation), and may be disabling:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pain </strong>– Pain is a frequent complaint and is attributed to joint, tendon, or muscle involvement. Pain may worsen at puberty and during intense physical efforts or menstrual periods. It can be more severe in the morning at awakening, presumably due to stasis and swelling [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Migraine</strong> – Migraine is frequently associated with VMs located in the temporal muscle. Involvement of the oral cavity, including the tongue, causes difficulty in speech and mastication. VMs located in the extremities often cause muscle weakness, limb length discrepancy, and hypoplasia of the affected side. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombosis</strong> – Thrombosis due to stagnant blood flow is common in VMs. It presents with rapid distension, firmness, and pain in the affected areas. However, VMs are unlikely to cause pulmonary embolism because the thrombosed channels are sequestered from the main conducting channels. Persistent thrombi can calcify, resulting in the formation of rounded, hyaline, organized thrombi (phleboliths) that may be palpable or visible on imaging. </p><p></p><p class="headingAnchor" id="H675540556"><span class="h2">Complications</span></p><p class="headingAnchor" id="H1744531509"><span class="h3">Localized intravascular coagulopathy</span><span class="headingEndMark"> — </span>Localized intravascular coagulopathy, also called chronic consumptive coagulopathy, occurs in approximately 42 percent of patients with large VMs [<a href="#rid35">35-39</a>]. Its severity depends upon the size and extension of VMs and is reflected by elevated D-dimer levels (&gt;0.5 mcg/mL). D-dimer levels are markedly elevated (&gt;1 mcg/mL) in 25 percent of patients with VMs, in the absence of other conditions associated with D-dimer increase, such as cancer, inflammatory diseases, or thrombophilia. (See <a class="local">'Coagulation abnormalities'</a> above.)</p><p>Localized intravascular coagulopathy is considered severe when high D-dimer levels (&gt;1.8 mcg/mL) are associated with low fibrinogen levels (&lt;150 mg/dL). Severe localized intravascular coagulopathy may progress to disseminated intravascular coagulation, with marked consumption of platelets, coagulation factors, and fibrinogen, and risk of severe bleeding during surgical procedures [<a href="#rid37">37,38,42</a>]. (See  <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a>.)</p><p class="headingAnchor" id="H3095660018"><span class="h3">Involvement of vital structures/organs</span><span class="headingEndMark"> — </span>Some VMs can be associated with life-threatening complications, due to extension to vital structures [<a href="#rid43">43</a>]. Deep oropharyngeal VMs compress and deviate the upper airways, causing snoring and sleep apnea. VMs invading the gastrointestinal or urogenital tract frequently cause bleeding and chronic anemia. Lesions involving bones predispose to pathologic fractures. </p><p class="headingAnchor" id="H1673530017"><span class="h2">Clinical variants</span></p><p class="headingAnchor" id="H2357683226"><span class="h3">Cutaneomucosal venous malformations</span><span class="headingEndMark"> — </span>Cutaneomucosal venous malformations (VMCMs; MIM #600195) are an uncommon type of VM inherited in an autosomal dominant fashion. VMCMs present as multiple small, superficial lesions of various hues of blue that are easily compressible. Lesions involve skin and oral mucosa  (<a class="graphic graphic_picture graphicRef113693" href="/z/d/graphic/113693.html" rel="external">picture 2</a>) and seldom invade the muscle. There are no reports of VMCMs extending to joint or bone. VMCMs involve the cervicofacial area in approximately 50 percent of cases and the extremities in 40 percent [<a href="#rid15">15</a>]. Due to their small size, they are usually asymptomatic and are not painful at compression.</p><p class="headingAnchor" id="H3230790013"><span class="h3">Multifocal venous malformations</span><span class="headingEndMark"> — </span>Multifocal venous malformations (MVMs) are similar to VMCM lesions but occur sporadically. They usually present as multiple small (&lt;5 cm in diameter), raised lesions of various hues of blue involving the skin, oral mucosa, and occasionally, the subcutaneous tissues  (<a class="graphic graphic_picture graphicRef113717" href="/z/d/graphic/113717.html" rel="external">picture 3</a>) and skeletal muscle. </p><p>MVMs are most frequently located in the cervicofacial area and extremities, typically have a hemispherical shape, are soft to the touch, and rarely emptied by external pressure. Due to their small size, these lesions are usually asymptomatic.</p><p class="headingAnchor" id="H557366348"><span class="h3">Glomuvenous malformations</span><span class="headingEndMark"> — </span>Glomuvenous malformations (GVMs) (formerly known as "capillary-lymphatic-venous malformations" glomangioma or glomangiomatosis) are a clinicopathologic variant of VMs characterized histologically by the presence of undifferentiated smooth muscle cells (glomus cells) surrounding convoluted venous channels. They may occur sporadically (de novo mutation) or, most commonly, be inherited in an autosomal dominant fashion (MIM #138000) [<a href="#rid14">14,15</a>].</p><p>GVMs present at birth as cobblestone or plaque-like, slightly hyperkeratotic, dark blue or purple, multifocal lesions of various sizes  (<a class="graphic graphic_picture graphicRef113694" href="/z/d/graphic/113694.html" rel="external">picture 4</a>). Lesions are more superficial than VMs, as they involve the skin and rarely the mucosae, but never extend deeply into muscles. In contrast with MVMs and VMCMs, GVMs are mainly located on the extremities, are often painful on palpation, and cannot be emptied by compression. Some patients with GVMs recall the appearance of new vascular lesions after trauma [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H641861170"><span class="h2">Mixed and syndromic venous malformations</span><span class="headingEndMark"> — </span>Venous anomalies can occur in combination with other vascular malformations, such as capillary-venous malformations and capillary-lymphatic-venous malformations. They usually involve cutaneous and subcutaneous tissues but rarely the muscle. Syndromes with a venous anomaly include the blue rubber bleb nevus (BRBN) syndrome, Maffucci syndrome, and Klippel-Trenaunay syndrome.</p><p class="headingAnchor" id="H2364468069"><span class="h3">Blue rubber bleb nevus syndrome</span><span class="headingEndMark"> — </span>Blue rubber bleb nevus (BRBN) syndrome (Bean syndrome) is a rare congenital disorder characterized by numerous, diffuse, cutaneous, and internal VMs. Patients with BRBN syndrome are often born with a so-called "dominant" lesion and with time develop multiple VMs that affect the skin, soft tissue, and gastrointestinal tract  (<a class="graphic graphic_picture graphicRef113695" href="/z/d/graphic/113695.html" rel="external">picture 5</a>) [<a href="#rid5">5</a>]. Skin lesions are often multiple, small, round, rubbery, and located on the palms and soles. Gastrointestinal sessile lesions cause chronic bleeding and anemia. Rarely, lesions may be found in other organs, such as the liver, spleen, bladder, kidney, lung, and brain [<a href="#rid5">5,44,45</a>]. </p><p class="headingAnchor" id="H3973377053"><span class="h3">Maffucci syndrome</span><span class="headingEndMark"> — </span>Maffucci syndrome is a rare, sporadic genetic syndrome characterized by multiple enchondromas, multiple superficial and subcutaneous spindle cell hemangiomas of the distal extremities  (<a class="graphic graphic_diagnosticimage graphicRef70081" href="/z/d/graphic/70081.html" rel="external">image 1</a>), and increased cancer risk [<a href="#rid43">43</a>]. The disease manifests during childhood with the development of multiple painful enchondromas in the bones of the hands and feet, as well as in the long bones. (See  <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">"Nonmalignant bone lesions in children and adolescents", section on 'Enchondroma'</a>.)</p><p>Spindle cell hemangiomas become apparent around puberty as subcutaneous red/brown or bluish vascular nodules located on the extremities and may progress to multifocal painful lesions over time. Histologically, spindle cell hemangiomas are benign vascular tumors composed of thin-walled, venous-like channels that may contain phleboliths, separated by areas of nodular proliferations of spindled fibroblastic cells. </p><p>With time, there is often severe disfiguration of the affected body parts  (<a class="graphic graphic_picture graphicRef113696" href="/z/d/graphic/113696.html" rel="external">picture 6</a>). Patients with Maffucci syndrome also have a high risk of malignancy, including chondrosarcoma, glioma, fibrosarcoma, and angiosarcoma [<a href="#rid46">46,47</a>]. </p><p class="headingAnchor" id="H561451219"><span class="h3">Klippel-Trenaunay syndrome</span><span class="headingEndMark"> — </span>Klippel-Trenaunay syndrome is a rare congenital disorder characterized by the presence of capillary-lymphatic-venous malformation or varicosities and limb overgrowth. The pathogenesis, clinical presentation, diagnosis, and management of Klippel-Trenaunay syndrome are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13730.html" rel="external">"Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H912898753"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1430314355"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>The diagnosis of VM should be suspected in patients presenting with a solitary, light to dark blue skin discoloration and an underlying soft, subcutaneous mass present since birth or early childhood. A history of slow growth over time or growth triggered by puberty, trauma, physical effort, or menstrual periods is an additional clue to the clinical diagnosis. A family history of similar lesions may suggest an inherited form. </p><p class="headingAnchor" id="H1238520197"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The clinical diagnosis is based upon the lesion appearance and characteristic findings on physical examination. </p><p>Common VMs range from small varicosities to extensive lesions of the face, extremities, or trunk. They can be emptied by compression and appear less prominent in the upright position. In contrast, they increase in volume with increasing venous pressure (eg, during Valsalva maneuver, crying, or straining), in a dependent position, or with exercise. Due to slow flow, there is <strong>no</strong> thrill or bruit, and the affected area is not warmer than the surrounding areas. Palpation is not painful unless thrombosis occurs. </p><p class="headingAnchor" id="H4108596843"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Superficial and localized lesions may not require imaging studies. In case of extensive lesions, Doppler ultrasonography and magnetic resonance imaging (MRI) represent the preferred methods for initial grading of VMs and post-treatment follow-up [<a href="#rid40">40</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Doppler ultrasonography</strong> – Doppler ultrasound can confirm a slow flow or the absence of flow within the malformation. Sometimes, flow may be observed when performing the Valsalva maneuver or compression. Generally, VMs appear as hypoechoic or heterogeneous and compressible. The detection of phleboliths further supports the diagnosis [<a href="#rid43">43,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI</strong> – MRI with contrast enhancement is the gold standard for assessing the VM extension and infiltration into adjacent organs and structures  (<a class="graphic graphic_diagnosticimage graphicRef113697" href="/z/d/graphic/113697.html" rel="external">image 2</a> and <a class="graphic graphic_picture graphicRef113698" href="/z/d/graphic/113698.html" rel="external">picture 7</a>). Gadolinium contrast allows a diffuse enhancement of venous channels (not observed in lymphatic malformations). Recommended sequences are T1- (pre- and post-contrast) and T2-weighted images with fat saturation. Typically, images may have intermediate signal intensity on T1 and hyperintense signal on T2 in relation to the content or the presence of hemorrhage or thrombosis. With T2-weighted images, phleboliths appear as focal areas of hypointense signal [<a href="#rid49">49,50</a>].</p><p></p><p>Lesions can be graded using MRI based upon the size and margins [<a href="#rid51">51,52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 1 – Well defined, ≤5 cm in diameter</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 2A – Well defined, &gt;5 cm in diameter</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 2B – Ill defined, ≤5 cm in diameter</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 3 – Ill defined, &gt;5 cm in diameter</p><p></p><p>This grading system has a prognostic significance and may predict the response to sclerotherapy. Small and well-defined lesions (grade 1) have a better therapeutic response to sclerotherapy than grade 3 lesions [<a href="#rid51">51</a>]. </p><p>Other imaging techniques that may be helpful include plain radiographs to detect pathognomonic phleboliths and computed tomography (CT) scans to evaluate bone infiltration. Phlebography (direct percutaneous contrast injection under fluoroscopy) is infrequently performed in the diagnostic setting. However, phlebography is usually performed prior to percutaneous sclerotherapy. (See <a class="local">'Sclerotherapy'</a> below.)</p><p class="headingAnchor" id="H4025113812"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Coagulation evaluation with measurement of blood levels of D-dimer and fibrinogen is indicated in patients with suspected large or multifocal VMs, with or without a history of thrombotic events. The finding of elevated D-dimer blood levels (&gt;0.5 mcg/mL) suggesting localized intravascular coagulopathy is pathognomonic of VMs. (See <a class="local">'Coagulation abnormalities'</a> above.)</p><p>D-dimer level is a helpful biomarker for the diagnosis of VMs, with high specificity but low sensitivity, as approximately 40 percent of patients with VMs have D-dimer levels &gt;0.5 mcg/mL and up to 25 percent have levels &gt;1 mcg/mL. When D-dimer levels are elevated in a patient with a VM without any concurrent disease that may induce a D-dimer increase, the likelihood that a venous component is present is approximately 96 percent [<a href="#rid37">37,38</a>]. This is true for pure, isolated VMs (unifocal or multifocal), as well as for mixed and syndromic lesions (capillary-venous malformation and Klippel-Trenaunay syndrome). However, normal D-dimer levels cannot rule out a VM because small VMs may have limited intravascular clotting that does not result in elevated D-dimer levels.</p><p>D-dimer levels are also helpful in differentiating among variants of VMs as well as in distinguishing VMs from other vascular anomalies. As an example, D-dimer levels are normal in glomuvenous malformations (GVMs), lymphatic malformations, Maffucci syndrome, and in fast-flow lesions (eg, arteriovenous malformations). D-dimer levels are elevated in the majority of patients with Klippel-Trenaunay syndrome but not in those with Parkes Weber syndrome, which is commonly misdiagnosed as Klippel-Trenaunay syndrome [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/13730.html" rel="external">"Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/13730.html" rel="external">"Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management", section on 'Parkes Weber syndrome'</a>.)</p><p class="headingAnchor" id="H1053507042"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>As diagnosis of VMs is usually based on clinical and imaging findings, biopsy is not usually required. Furthermore, biopsy is not always feasible due to the VM location and the increased risk of bleeding, which may result in inadequate sampling. However, if the diagnosis is in doubt, histopathologic and genetic analyses of a biopsy may be helpful for accurate diagnosis.</p><p class="headingAnchor" id="H2291622963"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of VMs includes several conditions presenting as "blue lesions":</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous angiosarcoma</strong> – Cutaneous angiosarcoma is a rare, aggressive, malignant tumor arising in either blood or lymphatic vessels and characterized by uncontrolled proliferation of vascular endothelial cells. It occurs more frequently in the head and neck areas of older adult males [<a href="#rid53">53</a>]. These tumors present as diffuse and ecchymotic macular, nodular, or plaque-like lesions with rapid expansive growth and tendency to ulcerate. Histopathologic examination clarifies the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/3367.html" rel="external">"Head and neck sarcomas", section on 'Angiosarcoma'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Collateral venous network</strong> – Collateral venous network can result from a severe stenosis or agenesia of a deep venous trunk and may be misdiagnosed as a VM. Such collateral venous networks are asymptomatic, and veins are histologically normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphatic malformations</strong> – Lymphatic malformations are often difficult to distinguish from VMs, particularly in case of hemorrhage into the lymphatic cysts, resulting in a blue coloration of the overlying skin. Compared with VMs, lymphatic malformations are not compressible. Ultrasonography shows hypo- or anechoic cysts with thick septa and fluid levels, although these pathognomonic signs are not always present. D-dimers are usually normal in lymphatic malformations, unless there is a large associated venous component, such as in Klippel-Trenaunay syndrome. Histopathologic examination of lymphatic malformations show positive D2-40 staining (podoplanin), a specific marker for lymphatic endothelial cells [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/5789.html" rel="external">"Vascular lesions in the newborn", section on 'Lymphatic malformations'</a> and  <a class="medical medical_review" href="/z/d/html/13730.html" rel="external">"Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subcutaneous (deep) infantile hemangiomas</strong> – Subcutaneous infantile hemangiomas can mimic VMs  (<a class="graphic graphic_picture graphicRef50388" href="/z/d/graphic/50388.html" rel="external">picture 8</a>). In contrast to VMs, this vascular tumor usually grows postnatally, between two weeks and two months of life, and regresses spontaneously from 10 to 12 months onwards during several years. Doppler ultrasound is the best examination to differentiate the fast-flow infantile hemangioma from the slow-flow VM. D-dimer levels are normal in infantile hemangiomas [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/5793.html" rel="external">"Infantile hemangiomas: Evaluation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital hemangiomas</strong> – Congenital hemangiomas are, like VMs, present and fully developed at birth. Depending on their evolution, they are classified in three types: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rapidly involuting congenital hemangioma (RICH), which regress spontaneously within the first year of life</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Noninvoluting congenital hemangioma (NICH), which remain stable and grow as the child grows</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Partially involuting congenital hemangioma (PICH), which regresses incompletely before stabilizing</p><p></p><p class="bulletIndent1">Congenital hemangiomas usually present as a single, well-limited, red-purple lesion with overlying telangiectasias surrounded by a pale, peripheral halo. NICHs are flat, while RICHs and PICHs exhibit exophytic presentations  (<a class="graphic graphic_picture graphicRef88800 graphicRef88907 graphicRef88948" href="/z/d/graphic/88800.html" rel="external">picture 9A-C</a>). Most congenital hemangiomas are localized on the limbs, followed by the head and neck region and the trunk. The size is usually &gt;2 cm in diameter [<a href="#rid55">55,56</a>].</p><p></p><p class="bulletIndent1">In contrast with VM, doppler examination of congenital hemangiomas reveals a high-flow vascular lesion. (See  <a class="medical medical_review" href="/z/d/html/13727.html" rel="external">"Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermal melanocytoses</strong> – Dermal melanocytoses, including the Mongolian spot, nevus of Ota, and blue nevi, arise from dermal melanocytes that never reached their normal site at the basal layer of the skin. The Mongolian spot is a congenital, large, macular, blue-gray pigmentation present in infants of East Asian ancestry (but not limited to them) that typically disappears with puberty. It is commonly located in the lumbosacral region  (<a class="graphic graphic_picture graphicRef77805" href="/z/d/graphic/77805.html" rel="external">picture 10</a>). Nevi of Ota and Ito are dermal melanocytoses that differ from the Mongolian spot by having a speckled, rather than uniform, appearance. The nevus of Ota manifests as a unilateral discoloration of the face involving the periorbital region, sclera, conjunctiva, temple, forehead, malar area, and nose  (<a class="graphic graphic_picture graphicRef77921" href="/z/d/graphic/77921.html" rel="external">picture 11</a>). The nevus of Ito is localized in the supraclavicular, scapular, and deltoid region  (<a class="graphic graphic_picture graphicRef94990" href="/z/d/graphic/94990.html" rel="external">picture 12</a>). The common blue nevus is a well-circumscribed blue nodule or macular plaque seen on any site of the body. (See  <a class="medical medical_review" href="/z/d/html/119230.html" rel="external">"Skin lesions in the newborn and infant", section on 'Dermal melanocytosis'</a> and  <a class="medical medical_review" href="/z/d/html/5560.html" rel="external">"Benign pigmented skin lesions other than melanocytic nevi (moles)", section on 'Congenital dermal melanocytosis (Mongolian spots)'</a>.)</p><p></p><p class="headingAnchor" id="H3855824556"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H2899619838"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>The management of patients with VMs involves an interdisciplinary team including a dermatologist, an interventional radiologist, a hematologist, a plastic and/or vascular surgeon, and an orthopedic surgeon as needed. Patients with small VMs and mild symptoms may not need treatment. Indications for treatment include esthetic disfigurement, functional impairment, and pain [<a href="#rid57">57,58</a>]. </p><p>The approach to management should be tailored for the individual patient, based upon location and extent of the malformation, clinical symptoms, and patient's preference [<a href="#rid58">58</a>]. The main therapeutic modalities include surgical resection and sclerotherapy. Supportive therapies include elastic compression and pain control. However, there are no randomized trials comparing the efficacy of these treatment modalities [<a href="#rid59">59</a>]. The choice of one modality over another or a combination of modalities is based upon limited evidence from observational studies, most of which have methodologic limitations, and clinical experience.</p><p class="headingAnchor" id="H2182238896"><span class="h2">Supportive therapies</span></p><p class="headingAnchor" id="H1831251906"><span class="h3">Compression</span><span class="headingEndMark"> — </span>Tailored compression garments are indicated for symptomatic and extensive VMs of the extremities to reduce pain and the risk of thrombosis. Compression is contraindicated in glomuvenous malformations (GVMs), as it increases pain, and is not effective in Maffucci syndrome.</p><p class="headingAnchor" id="H1472482463"><span class="h3">Pain control</span><span class="headingEndMark"> — </span>In patients in whom pain persists despite compression and in those with lesions in anatomic sites that are not amenable to compression, low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and/or anti-inflammatory drugs are a therapeutic option. When pain is associated with localized intravascular coagulopathy, low molecular weight heparin at a dose of 100 anti-factor Xa units/kg/day is introduced for 20 days, or longer if pain relapses [<a href="#rid37">37,43</a>]. (See  <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management", section on 'Low molecular weight heparin'</a>.)</p><p class="headingAnchor" id="H3924052866"><span class="h3">Coagulopathy control</span><span class="headingEndMark"> — </span>Localized intravascular coagulopathy is usually well tolerated in usual everyday life, but systemic activation may occur during surgery or other invasive procedures. Thus, coagulation evaluation with measurement of blood levels of D-dimer and fibrinogen is mandatory before starting any surgical treatment. Patients with evidence of localized intravascular coagulopathy (D-dimer &gt;0.5 mcg/mL) may develop disseminated intravascular coagulation with increased risk of bleeding during surgery. Preventive treatment with low molecular weight heparin at a prophylactic dose of 100 anti-Xa/kg/day should be started 24 hours prior to any surgical procedure for a total of five to seven days [<a href="#rid37">37,38</a>]. Consultation with hematology is indicated if high levels of D-dimer are associated with low fibrinogen.</p><p class="headingAnchor" id="H2257787650"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Surgery may be a therapeutic option for small VMs amenable to complete excision or for larger VMs with well-defined margins. Surgery alone is often performed for the treatment of GVMs due to their small size and low degree of invasion through adjacent tissues.</p><p>For large VMs, surgery is rarely performed without prior sclerotherapy, due to difficulty obtaining surgical free margins, elevated risk of relapse, and high surgical morbidity. Surgical techniques may include simple excision and repair, skin graft, local skin expanders, or free fasciocutaneous or muscle flaps, depending upon the size and location of the malformation. </p><p>Coagulation evaluation with measurement of blood levels of D-dimer and fibrinogen is mandatory before starting any surgical treatment. Patients with high D-dimers and normal or low fibrinogen should receive prophylactic low molecular weight heparin 24 hours prior to surgery and for five to seven days postoperatively to avoid intraoperative and/or postoperative bleeding [<a href="#rid37">37,60</a>].</p><p class="headingAnchor" id="H2856291366"><span class="h2">Sclerotherapy</span><span class="headingEndMark"> — </span>Sclerotherapy is an alternative invasive treatment option. The use of sclerotherapy and surgery varies in different centers, depending on the specialties involved and their expertise in managing vascular anomalies. In many multidisciplinary centers both are used sequentially. </p><p>Sclerotherapy is in most cases performed before surgical treatment to diminish the volume of the malformation. However, sclerotherapy may be the sole treatment in patients in whom surgery is technically not feasible. Several sessions may be necessary. </p><p>In each session, the injection of a sclerosant agent is preceded by a direct percutaneous phlebography that allows evaluation of the VM architecture, flow rate, rate of venous drainage, and volume of contrast distribution [<a href="#rid40">40</a>]. In children with extensive head and neck malformations that involve the airways, it is necessary to consider performing a tracheostomy prior to sclerotherapy or having the child on mechanical ventilation for 48 to 72 hours after the procedure.</p><p>A variety of sclerosing agents can be used to obliterate vascular channels. They are irritant chemicals that cause damage to the vascular endothelium with subsequent inflammation and fibrosis. (See  <a class="medical medical_review" href="/z/d/html/8206.html" rel="external">"Injection sclerotherapy techniques for the treatment of telangiectasias, reticular veins, and small varicose veins"</a>.)</p><p>Due to the lack of large randomized trials, it remains unclear which sclerosing agent is superior in terms of efficacy and safety [<a href="#rid52">52,59,61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethanol</strong> – Absolute ethanol has been considered to be the most effective sclerosant, but it can cause potentially severe side effects [<a href="#rid62">62,63</a>]. Therefore, it should only be used by experienced interventional radiologists in a hospital setting [<a href="#rid52">52</a>]. A systematic review found that ethanol provides an average response rate, defined as improvement in symptoms or reduction in VM size, of approximately 74 percent (range, 27 to 100 percent) [<a href="#rid59">59</a>]. Ethanol is, however, a highly toxic agent with a rate of serious local and systemic complications between 8 and 28 percent [<a href="#rid59">59,61,64</a>]. Local complications, such as skin necrosis, pain, and blistering, are the most common side effects, occurring in approximately 8 percent of patients. Other possible complications include peripheral nerve injury (2 to 10 percent), transient pain, muscle contracture, deep vein thrombosis, pulmonary embolus, and cardiopulmonary collapse [<a href="#rid52">52,62,65</a>]. </p><p></p><p class="bulletIndent1">The quantity of ethanol can be reduced by the addition of ethylcellulose (gelified ethanol), as ethanol is trapped in the malformation by ethylcellulose, resulting in a prolonged contact time of ethanol with the vasculature. Efficacy on pain and functional and esthetic impairment seems to be similar to that reported with ethanol, but in contrast with absolute ethanol, which is administered under general anesthesia, gelified ethanol can be used under local anesthesia for the treatment of superficial lesions [<a href="#rid66">66</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleomycin</strong> – Another sclerosing agent that has been shown to be effective for slow-flow vascular malformations, including VMs, is <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, a cytotoxic antitumoral agent [<a href="#rid67">67-69</a>]. In contrast to ethanol, bleomycin causes minimal swelling and is not neurotoxic, allowing its use in complicated areas, such as those in close contact with nerves, the airway, or the orbit. Bleomycin is especially indicated in areas with high risk for complications when using alcohol. </p><p></p><p class="bulletIndent1">A concern that still needs to be addressed is the long-term risk of pulmonary fibrosis, the major complication of intravenous administration of <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> [<a href="#rid70">70</a>]. This complication has been seen in cancer patients and depends on lifetime accumulated dose. A lifetime dose of 5 mg/kg should not be exceeded. There are no reports of pulmonary fibrosis associated with bleomycin treatment of vascular anomalies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents</strong> – Other sclerosing agents that have been used for the treatment of VMs include detergents, such as <a class="drug drug_general" data-topicid="9907" href="/z/d/drug information/9907.html" rel="external">polidocanol</a>, <a class="drug drug_general" data-topicid="10330" href="/z/d/drug information/10330.html" rel="external">sodium tetradecyl sulfate</a> (STS), and microfoams [<a href="#rid71">71-77</a>]. Their superiority in terms of effectiveness compared with absolute ethanol has yet to be demonstrated [<a href="#rid52">52</a>]. Moreover, even if the overall rate of complications seems lower compared with ethanol sclerotherapy, severe adverse events have been reported with foam sclerotherapy [<a href="#rid78">78-81</a>]. </p><p></p><p class="headingAnchor" id="H1659416966"><span class="h2">Sirolimus</span><span class="headingEndMark"> — </span>The mammalian target of rapamycin (mTOR) inhibitor <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> (rapamycin) has emerged as a promising targeted therapy for VMs. </p><p>In murine models of VM (see <a class="local">'Animal models'</a> above), <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> was shown to decrease the proliferation of endothelial cells and inhibit the excessive activation of AKT, which is responsible for smooth muscle deficiency [<a href="#rid33">33</a>]. Sirolimus was also shown to facilitate the nuclear localization of FOXO1 and the expression of platelet-derived growth factor-beta (PDGF-beta) in mutant endothelial cells, improving paracrine interactions between endothelial cells and smooth muscle cells [<a href="#rid34">34</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> has shown efficacy in patients with VMs refractory to surgery and/or sclerotherapy and in patients in whom these treatments are not feasible. Sirolimus is not yet approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for venous malformations, yet it is used off-label worldwide. There are no guidelines regarding the management of VMs with sirolimus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – In adults, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> is given at the dose of 2 mg once daily. In children younger than 18 years, the recommended dose is 0.8 mg/m<sup>2</sup>/day in two divided doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The results of preliminary studies indicate that <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> is a useful addition to the available treatments for VMs [<a href="#rid82">82</a>]. Similar encouraging results have been reported with sirolimus treatment in several case studies of blue rubber bleb nevus (BRBN) syndrome, lymphatic malformations, and mixed malformations [<a href="#rid83">83-86</a>]. However, the optimal length of sirolimus treatment, timing of administration (before and/or after surgery or sclerotherapy), and its long-term safety remain to be determined. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a pilot study of six patients with VMs refractory to standard treatments, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> induced pain relief, functional improvement of the affected body part, and improved self-perceived quality of life in all patients [<a href="#rid33">33</a>]. Sirolimus had an on/off effect on bleeding and oozing in patients with lymphatic malformations. Biologic markers (D-dimers and fibrinogen) improved, and MRIs showed significant decrease in volume after 12 months of treatment. Sirolimus was well tolerated in all these patients. Minor adverse effects included mucositis (50 percent), fatigue (33 percent), headache (33 percent), cutaneous rash (17 percent), and diarrhea (17 percent), all easily managed with symptomatic treatment. One patient presented a grade 3 stomatitis necessitating cessation of sirolimus, and one patient with prior history of cutaneous basocellular carcinoma presented with a basocellular carcinoma after one year on treatment. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A phase 2 trial evaluated <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> in 19 patients with slow-flow malformations, including seven patients with VMs, six patients with lymphatic malformations, two patients with generalized lymphatic anomaly, one patient with capillary-venous malformations, two patients with Klippel-Trenaunay syndrome, and one patient with phosphatase and tensin homolog (PTEN) hamartoma syndrome. After one year of treatment, all patients experienced improved mobility or organ function; reduction of pain, bleeding, or oozing; or reduction or cessation of infections. These improvements appeared within three months from the start of sirolimus and were maintained. Although no clinical disappearance of the lesions was observed, the volume reduction induced by sirolimus allowed for the subsequent conventional treatment of two patients (sclerotherapy and surgery). Sirolimus was well tolerated; headache, skin rash, mucositis, fatigue, and diarrhea were the most frequent grade 1 to 2 adverse events. All were easily manageable with symptomatic treatment or temporary arrest. Mucositis was the most common grade 3 adverse event and led to definitive discontinuation of sirolimus in two patients (10.6 percent) despite dose adjustment [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1">The impact of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> on the VM volume remains unclear:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a prospective, multicentric, phase 2 trial, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> was evaluated in 126 children (0 to 14 years) with uncontrollable, complicated vascular anomalies, including 25 patients (20 percent) with kaposiform hemangioendothelioma, 19 patients (15 percent) with VMs, and 20 patients (16 percent) with lymphatic malformations [<a href="#rid88">88</a>]. Sirolimus was given for 12 months. The primary endpoint was the radiologic response. Twenty-one percent of patients with VMs presented a radiologic decrease of ≥75 percent compared with 10 percent of patients with lymphatic malformations. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another multicenter trial, 59 children (6 to 18 years) with slow-flow vascular malformations (22 patients with a VM, 18 with a lymphatic malformation, and 19 with a combined malformation) received oral <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> after an observation period [<a href="#rid89">89</a>]. The primary outcome was change in radiologic volume. Sirolimus improved symptoms (ie, pain, oozing, bleeding) and quality of life. However, there was no clinically significant decrease in volume compared with the observation phase.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prospective, multicentric, phase 3 single arm trial (VASE, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT02638389&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSxaC2JlixNz3TP5F8Q3Gpsce8RqFR4rv%2BXGLICQZBD9WQ%3D%3D&amp;TOPIC_ID=110155" target="_blank">NCT02638389</a>; European Union Drug Regulation Authorities Clinical Trials [EudraCT] Number: 2015-001703-32) is underway in Europe to evaluate the efficacy of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> in pediatric and adult patients with VMs that are refractory to standard treatment. In this trial, sirolimus is given for a planned treatment duration of two years. Genomic analysis will be correlated with sirolimus efficacy and symptomatology evolution after stopping sirolimus therapy.</p><p></p><p class="headingAnchor" id="H1389383782"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Regular clinical, imaging, and laboratory follow-up is indicated in all patients with VMs. Lesions often expand around puberty or during pregnancy, due to hormonal changes, and can become symptomatic. Coagulation evaluation is mandatory in all patients with VMs and before any therapeutic intervention or surgical procedure. Patients with evidence of localized intravascular coagulopathy are at risk of developing disseminated intravascular coagulopathy with increased risk of bleeding during and after surgery. (See <a class="local">'Coagulopathy control'</a> above and  <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>.) </p><p>Most patients with Klippel-Trenaunay syndrome have chronic localized intravascular coagulopathy and need careful follow-up to detect venous thrombosis and/or pulmonary embolism. In these patients, however, elevated D-dimer levels cannot be used to screen for recent thrombosis. (See  <a class="medical medical_review" href="/z/d/html/13730.html" rel="external">"Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management", section on 'Clotting disorders and thromboembolism'</a>.) </p><p>Patients with Maffucci syndrome need close follow-up due to the high risk of developing malignancies, such as chondrosarcoma, glioma, fibrosarcoma, and angiosarcoma [<a href="#rid21">21,90</a>]. </p><p class="headingAnchor" id="H338275492"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Curative treatment of VMs is rarely possible and recurrence is common. Some patients may return 5 to 10 years later with symptoms and evidence of recurrent disease at a previously treated site. Patients with extensive disease may require repeated treatments over time and multimodal therapeutic strategies to control the disease. </p><p class="headingAnchor" id="H3747284721"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122193.html" rel="external">"Society guideline links: Vascular anomalies"</a>.)</p><p class="headingAnchor" id="H3177439393"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Venous malformations (VMs) are rare, slow-flow vascular malformations resulting from inborn errors in the development of the venous network. In most cases, VMs occur sporadically, but they can rarely be inherited in an autosomal dominant fashion. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – VMs consist of dilated and dysfunctional veins that are deficient in smooth muscle cells. The slow flow through the dilated and ectatic vessels results in blood stagnation and localized intravascular coagulation, reflected by elevated blood levels of D-dimer (&gt;0.5 mcg/mL) and normal or low fibrinogen. (See <a class="local">'Vascular changes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – VMs typically manifest as a light to dark blue skin discoloration overlying a soft, compressible, subcutaneous mass  (<a class="graphic graphic_picture graphicRef105862" href="/z/d/graphic/105862.html" rel="external">picture 1</a>). They are present at birth, grow with the child, and slowly expand over time. However, the clinical presentation may be highly variable, depending upon the size, location, and mass effect of the lesion on the adjacent organs. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of VM is based upon the clinical finding of a solitary blue lesion present since birth that is soft and compressible and not painful on palpation. Typically, there is <strong>no</strong> thrill or bruit, and the affected area is not warmer than the surrounding areas. Doppler ultrasound and MRI can confirm the diagnosis and assess the VM extension and infiltration into adjacent organs and structures. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of patients with VMs involves an interdisciplinary team including a dermatologist, an interventional radiologist, a hematologist, a plastic and/or vascular surgeon, and an orthopedic surgeon as needed, ideally in a specialized center for vascular anomalies. Treatment should be individualized and may include supportive therapies, surgery, sclerotherapy, and <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, alone or in combination. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive measures </strong>–<strong> </strong>Supportive therapies include compression, nonsteroidal anti-inflammatory drugs (NSAIDs) for pain control, and management of localized intravascular coagulation. For patients with evidence of localized intravascular coagulopathy and elevated D-dimer (&gt;0.5 mcg/mL), we suggest anticoagulation using low molecular weight heparin rather than no anticoagulation or other anticoagulants (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional management </strong>– Patients with mild symptoms may not need further treatment. For lesions causing esthetic disfigurement, functional impairment, or pain, we suggest surgery, if feasible, with or without sclerotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Sclerotherapy may be used for larger lesions prior to surgery to diminish volume and improve surgical outcomes. However, for lesions not amenable to surgical resection, sclerotherapy may be the sole treatment. For lesions that are not amenable to or are refractory to surgery and sclerotherapy, we suggest <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wassef M, Blei F, Adams D, et al. Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies. Pediatrics 2015; 136:e203.</a></li><li><a class="nounderline abstract_t">Nguyen HL, Bonadurer GF 3rd, Tollefson MM. Vascular Malformations and Health-Related Quality of Life: A Systematic Review and Meta-analysis. JAMA Dermatol 2018; 154:661.</a></li><li><a class="nounderline abstract_t">Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet 2007; 16 Spec No. 2:R140.</a></li><li><a class="nounderline abstract_t">Limaye N, Boon LM, Vikkula M. From germline towards somatic mutations in the pathophysiology of vascular anomalies. Hum Mol Genet 2009; 18:R65.</a></li><li><a class="nounderline abstract_t">Soblet J, Kangas J, Nätynki M, et al. Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations. J Invest Dermatol 2017; 137:207.</a></li><li><a class="nounderline abstract_t">Vikkula M, Boon LM, Carraway KL 3rd, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996; 87:1181.</a></li><li><a class="nounderline abstract_t">Limaye N, Wouters V, Uebelhoer M, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009; 41:118.</a></li><li><a class="nounderline abstract_t">Soblet J, Limaye N, Uebelhoer M, et al. Variable Somatic TIE2 Mutations in Half of Sporadic Venous Malformations. Mol Syndromol 2013; 4:179.</a></li><li><a class="nounderline abstract_t">Wouters V, Limaye N, Uebelhoer M, et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet 2010; 18:414.</a></li><li><a class="nounderline abstract_t">Calvert JT, Riney TJ, Kontos CD, et al. Allelic and locus heterogeneity in inherited venous malformations. Hum Mol Genet 1999; 8:1279.</a></li><li class="breakAll">Seront E, Boon LM, Vikkula M. TEK-related venous malformations. In: GeneReviews, Adam MP, Mirzaa GM, Pagon RA, et al (Eds), University of Washington, Seattle, 1993.</li><li><a class="nounderline abstract_t">Limaye N, Kangas J, Mendola A, et al. Somatic Activating PIK3CA Mutations Cause Venous Malformation. Am J Hum Genet 2015; 97:914.</a></li><li><a class="nounderline abstract_t">Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94:455.</a></li><li><a class="nounderline abstract_t">Brouillard P, Boon LM, Mulliken JB, et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas"). Am J Hum Genet 2002; 70:866.</a></li><li><a class="nounderline abstract_t">Boon LM, Mulliken JB, Enjolras O, Vikkula M. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol 2004; 140:971.</a></li><li><a class="nounderline abstract_t">Amyere M, Aerts V, Brouillard P, et al. Somatic uniparental isodisomy explains multifocality of glomuvenous malformations. Am J Hum Genet 2013; 92:188.</a></li><li><a class="nounderline abstract_t">Revencu N, Vikkula M. Cerebral cavernous malformation: new molecular and clinical insights. J Med Genet 2006; 43:716.</a></li><li><a class="nounderline abstract_t">Sirvente J, Enjolras O, Wassef M, et al. Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations. J Eur Acad Dermatol Venereol 2009; 23:1066.</a></li><li><a class="nounderline abstract_t">Toll A, Parera E, Giménez-Arnau AM, et al. Cutaneous venous malformations in familial cerebral cavernomatosis caused by KRIT1 gene mutations. Dermatology 2009; 218:307.</a></li><li><a class="nounderline abstract_t">de Vos IJ, Vreeburg M, Koek GH, van Steensel MA. Review of familial cerebral cavernous malformations and report of seven additional families. Am J Med Genet A 2017; 173:338.</a></li><li><a class="nounderline abstract_t">Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011; 43:1256.</a></li><li><a class="nounderline abstract_t">Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011; 43:1262.</a></li><li><a class="nounderline abstract_t">Amyere M, Dompmartin A, Wouters V, et al. Common somatic alterations identified in maffucci syndrome by molecular karyotyping. Mol Syndromol 2014; 5:259.</a></li><li><a class="nounderline abstract_t">Uebelhoer M, Nätynki M, Kangas J, et al. Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. Hum Mol Genet 2013; 22:3438.</a></li><li><a class="nounderline abstract_t">Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118:149.</a></li><li><a class="nounderline abstract_t">De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8:211.</a></li><li><a class="nounderline abstract_t">Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87:1161.</a></li><li><a class="nounderline abstract_t">Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87:1171.</a></li><li><a class="nounderline abstract_t">Kim I, Kim HG, So JN, et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. Circ Res 2000; 86:24.</a></li><li><a class="nounderline abstract_t">Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274.</a></li><li><a class="nounderline abstract_t">Hu HT, Huang YH, Chang YA, et al. Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression. J Invest Dermatol 2008; 128:2325.</a></li><li><a class="nounderline abstract_t">Korpelainen EI, Kärkkäinen M, Gunji Y, et al. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 1999; 18:1.</a></li><li><a class="nounderline abstract_t">Boscolo E, Limaye N, Huang L, et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest 2015; 125:3491.</a></li><li><a class="nounderline abstract_t">Si Y, Huang J, Li X, et al. AKT/FOXO1 axis links cross-talking of endothelial cell and pericyte in TIE2-mutated venous malformations. Cell Commun Signal 2020; 18:139.</a></li><li><a class="nounderline abstract_t">Mazoyer E, Enjolras O, Bisdorff A, et al. Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol 2008; 144:861.</a></li><li><a class="nounderline abstract_t">Hermans C, Dessomme B, Lambert C, Deneys V. [Venous malformations and coagulopathy]. Ann Chir Plast Esthet 2006; 51:388.</a></li><li><a class="nounderline abstract_t">Dompmartin A, Acher A, Thibon P, et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol 2008; 144:873.</a></li><li><a class="nounderline abstract_t">Dompmartin A, Ballieux F, Thibon P, et al. Elevated D-dimer level in the differential diagnosis of venous malformations. Arch Dermatol 2009; 145:1239.</a></li><li><a class="nounderline abstract_t">Hung JW, Leung MW, Liu CS, et al. Venous Malformation and Localized Intravascular Coagulopathy in Children. Eur J Pediatr Surg 2017; 27:181.</a></li><li><a class="nounderline abstract_t">Behravesh S, Yakes W, Gupta N, et al. Venous malformations: clinical diagnosis and treatment. Cardiovasc Diagn Ther 2016; 6:557.</a></li><li><a class="nounderline abstract_t">Casanova D, Boon LM, Vikkula M. [Venous malformations: clinical characteristics and differential diagnosis]. Ann Chir Plast Esthet 2006; 51:373.</a></li><li><a class="nounderline abstract_t">Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol 1997; 13:375.</a></li><li><a class="nounderline abstract_t">Dompmartin A, Vikkula M, Boon LM. Venous malformation: update on aetiopathogenesis, diagnosis and management. Phlebology 2010; 25:224.</a></li><li><a class="nounderline abstract_t">Fishman SJ, Smithers CJ, Folkman J, et al. Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding. Ann Surg 2005; 241:523.</a></li><li><a class="nounderline abstract_t">Wassef M, Vanwijck R, Clapuyt P, et al. [Vascular tumours and malformations, classification, pathology and imaging]. Ann Chir Plast Esthet 2006; 51:263.</a></li><li><a class="nounderline abstract_t">Enjolras O, Wassef M, Merland JJ. [Maffucci syndrome: a false venous malformation? A case with hemangioendothelioma with fusiform cells]. Ann Dermatol Venereol 1998; 125:512.</a></li><li><a class="nounderline abstract_t">Schwartz HS, Zimmerman NB, Simon MA, et al. The malignant potential of enchondromatosis. J Bone Joint Surg Am 1987; 69:269.</a></li><li><a class="nounderline abstract_t">Trop I, Dubois J, Guibaud L, et al. Soft-tissue venous malformations in pediatric and young adult patients: diagnosis with Doppler US. Radiology 1999; 212:841.</a></li><li><a class="nounderline abstract_t">Dubois J, Soulez G, Oliva VL, et al. Soft-tissue venous malformations in adult patients: imaging and therapeutic issues. Radiographics 2001; 21:1519.</a></li><li><a class="nounderline abstract_t">Konez O, Burrows PE. Magnetic resonance of vascular anomalies. Magn Reson Imaging Clin N Am 2002; 10:363.</a></li><li><a class="nounderline abstract_t">Goyal M, Causer PA, Armstrong D. Venous vascular malformations in pediatric patients: comparison of results of alcohol sclerotherapy with proposed MR imaging classification. Radiology 2002; 223:639.</a></li><li><a class="nounderline abstract_t">Burrows PE, Mason KP. Percutaneous treatment of low flow vascular malformations. J Vasc Interv Radiol 2004; 15:431.</a></li><li><a class="nounderline abstract_t">Albores-Saavedra J, Schwartz AM, Henson DE, et al. Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007. Ann Diagn Pathol 2011; 15:93.</a></li><li><a class="nounderline abstract_t">Paltiel HJ, Burrows PE, Kozakewich HP, et al. Soft-tissue vascular anomalies: utility of US for diagnosis. Radiology 2000; 214:747.</a></li><li><a class="nounderline abstract_t">Boon LM, Enjolras O, Mulliken JB. Congenital hemangioma: evidence of accelerated involution. J Pediatr 1996; 128:329.</a></li><li><a class="nounderline abstract_t">Enjolras O, Mulliken JB, Boon LM, et al. Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly. Plast Reconstr Surg 2001; 107:1647.</a></li><li><a class="nounderline abstract_t">Enjolras O. Classification and management of the various superficial vascular anomalies: hemangiomas and vascular malformations. J Dermatol 1997; 24:701.</a></li><li><a class="nounderline abstract_t">Dompmartin A, Baselga E, Boon LM, et al. The VASCERN-VASCA Working Group Diagnostic and Management Pathways for Venous Malformations. J Vasc Anom (Phila) 2023; 4:e064.</a></li><li><a class="nounderline abstract_t">van der Vleuten CJ, Kater A, Wijnen MH, et al. Effectiveness of sclerotherapy, surgery, and laser therapy in patients with venous malformations: a systematic review. Cardiovasc Intervent Radiol 2014; 37:977.</a></li><li><a class="nounderline abstract_t">Boon LM, Vanwijck R. [Medical and surgical treatment of venous malformations]. Ann Chir Plast Esthet 2006; 51:403.</a></li><li><a class="nounderline abstract_t">Horbach SE, Lokhorst MM, Saeed P, et al. Sclerotherapy for low-flow vascular malformations of the head and neck: A systematic review of sclerosing agents. J Plast Reconstr Aesthet Surg 2016; 69:295.</a></li><li><a class="nounderline abstract_t">Hammer FD, Boon LM, Mathurin P, Vanwijck RR. Ethanol sclerotherapy of venous malformations: evaluation of systemic ethanol contamination. J Vasc Interv Radiol 2001; 12:595.</a></li><li><a class="nounderline abstract_t">Yakes WF, Haas DK, Parker SH, et al. Symptomatic vascular malformations: ethanol embolotherapy. Radiology 1989; 170:1059.</a></li><li><a class="nounderline abstract_t">Lee BB, Do YS, Byun HS, et al. Advanced management of venous malformation with ethanol sclerotherapy: mid-term results. J Vasc Surg 2003; 37:533.</a></li><li><a class="nounderline abstract_t">Mason KP, Michna E, Zurakowski D, et al. Serum ethanol levels in children and adults after ethanol embolization or sclerotherapy for vascular anomalies. Radiology 2000; 217:127.</a></li><li><a class="nounderline abstract_t">Dompmartin A, Blaizot X, Théron J, et al. Radio-opaque ethylcellulose-ethanol is a safe and efficient sclerosing agent for venous malformations. Eur Radiol 2011; 21:2647.</a></li><li><a class="nounderline abstract_t">Muir T, Kirsten M, Fourie P, et al. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int 2004; 19:766.</a></li><li><a class="nounderline abstract_t">Legiehn GM, Heran MK. A Step-by-Step Practical Approach to Imaging Diagnosis and Interventional Radiologic Therapy in Vascular Malformations. Semin Intervent Radiol 2010; 27:209.</a></li><li><a class="nounderline abstract_t">Horbach SER, Rigter IM, Smitt JHS, et al. Intralesional Bleomycin Injections for Vascular Malformations: A Systematic Review and Meta-Analysis. Plast Reconstr Surg 2016; 137:244.</a></li><li><a class="nounderline abstract_t">Bechard DE, Fairman RP, DeBlois GG, Via CT. Fatal pulmonary fibrosis from low-dose bleomycin therapy. South Med J 1987; 80:646.</a></li><li><a class="nounderline abstract_t">Siniluoto TM, Svendsen PA, Wikholm GM, et al. Percutaneous sclerotherapy of venous malformations of the head and neck using sodium tetradecyl sulphate (sotradecol). Scand J Plast Reconstr Surg Hand Surg 1997; 31:145.</a></li><li><a class="nounderline abstract_t">Duffy DM. Sclerosants: a comparative review. Dermatol Surg 2010; 36 Suppl 2:1010.</a></li><li><a class="nounderline abstract_t">Tan KT, Kirby J, Rajan DK, et al. Percutaneous sodium tetradecyl sulfate sclerotherapy for peripheral venous vascular malformations: a single-center experience. J Vasc Interv Radiol 2007; 18:343.</a></li><li><a class="nounderline abstract_t">Stimpson P, Hewitt R, Barnacle A, et al. Sodium tetradecyl sulphate sclerotherapy for treating venous malformations of the oral and pharyngeal regions in children. Int J Pediatr Otorhinolaryngol 2012; 76:569.</a></li><li><a class="nounderline abstract_t">Yamaki T, Nozaki M, Sakurai H, et al. Prospective randomized efficacy of ultrasound-guided foam sclerotherapy compared with ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous malformations. J Vasc Surg 2008; 47:578.</a></li><li><a class="nounderline abstract_t">Gulsen F, Cantasdemir M, Solak S, et al. Percutaneous sclerotherapy of peripheral venous malformations in pediatric patients. Pediatr Surg Int 2011; 27:1283.</a></li><li><a class="nounderline abstract_t">Cabrera J, Cabrera J Jr, Garcia-Olmedo MA, Redondo P. Treatment of venous malformations with sclerosant in microfoam form. Arch Dermatol 2003; 139:1409.</a></li><li><a class="nounderline abstract_t">Forlee MV, Grouden M, Moore DJ, Shanik G. Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 2006; 43:162.</a></li><li><a class="nounderline abstract_t">Li L, Feng J, Zeng XQ, Li YH. Fluoroscopy-guided foam sclerotherapy with sodium morrhuate for peripheral venous malformations: Preliminary experience. J Vasc Surg 2009; 49:961.</a></li><li><a class="nounderline abstract_t">Marrocco-Trischitta MM, Guerrini P, Abeni D, Stillo F. Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation. Dermatol Surg 2002; 28:153.</a></li><li><a class="nounderline abstract_t">Potter B, Gobeil F, Oiknine A, Laramée P. The first case of takotsubo cardiomyopathy associated with sodium tetradecyl sulphate sclerotherapy. Can J Cardiol 2010; 26:146.</a></li><li><a class="nounderline abstract_t">Seront E, Van Damme A, Boon LM, Vikkula M. Rapamycin and treatment of venous malformations. Curr Opin Hematol 2019; 26:185.</a></li><li><a class="nounderline abstract_t">Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics 2016; 137:e20153257.</a></li><li><a class="nounderline abstract_t">Salloum R, Fox CE, Alvarez-Allende CR, et al. Response of Blue Rubber Bleb Nevus Syndrome to Sirolimus Treatment. Pediatr Blood Cancer 2016; 63:1911.</a></li><li><a class="nounderline abstract_t">Yesil S, Tanyildiz HG, Bozkurt C, et al. Single-center experience with sirolimus therapy for vascular malformations. Pediatr Hematol Oncol 2016; 33:219.</a></li><li><a class="nounderline abstract_t">Wong XL, Phan K, Rodríguez Bandera AI, Sebaratnam DF. Sirolimus in blue rubber bleb naevus syndrome: A systematic review. J Paediatr Child Health 2019; 55:152.</a></li><li><a class="nounderline abstract_t">Hammer J, Seront E, Duez S, et al. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study. Orphanet J Rare Dis 2018; 13:191.</a></li><li><a class="nounderline abstract_t">Ji Y, Chen S, Yang K, et al. A prospective multicenter study of sirolimus for complicated vascular anomalies. J Vasc Surg 2021; 74:1673.</a></li><li><a class="nounderline abstract_t">Maruani A, Tavernier E, Boccara O, et al. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial. JAMA Dermatol 2021; 157:1289.</a></li><li><a class="nounderline abstract_t">Verdegaal SH, Bovée JV, Pansuriya TC, et al. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist 2011; 16:1771.</a></li></ol></div><div id="topicVersionRevision">Topic 110155 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26055853" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562060" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vascular Malformations and Health-Related Quality of Life: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17670762" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Genetic causes of vascular malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19297403" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : From germline towards somatic mutations in the pathophysiology of vascular anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27519652" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8980225" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19079259" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801934" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Variable Somatic TIE2 Mutations in Half of Sporadic Venous Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19888299" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369874" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Allelic and locus heterogeneity in inherited venous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369874" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Allelic and locus heterogeneity in inherited venous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26637981" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Somatic Activating PIK3CA Mutations Cause Venous Malformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449998" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mutation of the PIK3CA oncogene in human cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11845407" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas").</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15313813" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375657" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Somatic uniparental isodisomy explains multifocality of glomuvenous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16571644" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cerebral cavernous malformation: new molecular and clinical insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453802" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19182478" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cutaneous venous malformations in familial cerebral cavernomatosis caused by KRIT1 gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27792856" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Review of familial cerebral cavernous malformations and report of seven additional families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22057234" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22057236" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25565925" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Common somatic alterations identified in maffucci syndrome by molecular karyotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633549" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15260986" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169466" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8980223" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8980224" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10625301" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22500797" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : mTOR signaling in growth control and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18401423" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9926914" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26258417" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32867785" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : AKT/FOXO1 axis links cross-talking of endothelial cell and pericyte in TIE2-mutated venous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645137" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005308" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : [Venous malformations and coagulopathy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645138" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association of localized intravascular coagulopathy with venous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917952" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Elevated D-dimer level in the differential diagnosis of venous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27089461" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Venous Malformation and Localized Intravascular Coagulopathy in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28123976" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Venous malformations: clinical diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17007984" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : [Venous malformations: clinical characteristics and differential diagnosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9551150" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Vascular tumors and vascular malformations (new issues).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20870869" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Venous malformation: update on aetiopathogenesis, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729077" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005309" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : [Vascular tumours and malformations, classification, pathology and imaging].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9747318" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : [Maffucci syndrome: a false venous malformation? A case with hemangioendothelioma with fusiform cells].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805090" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The malignant potential of enchondromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10478255" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Soft-tissue venous malformations in pediatric and young adult patients: diagnosis with Doppler US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11706222" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Soft-tissue venous malformations in adult patients: imaging and therapeutic issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12424951" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Magnetic resonance of vascular anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12034929" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Venous vascular malformations in pediatric patients: comparison of results of alcohol sclerotherapy with proposed MR imaging classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126652" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Percutaneous treatment of low flow vascular malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190880" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10715041" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Soft-tissue vascular anomalies: utility of US for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774499" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Congenital hemangioma: evidence of accelerated involution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11391180" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9433027" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Classification and management of the various superficial vascular anomalies: hemangiomas and vascular malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37332880" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The VASCERN-VASCA Working Group Diagnostic and Management Pathways for Venous Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24196269" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effectiveness of sclerotherapy, surgery, and laser therapy in patients with venous malformations: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005307" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : [Medical and surgical treatment of venous malformations].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26723834" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sclerotherapy for low-flow vascular malformations of the head and neck: A systematic review of sclerosing agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11340138" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ethanol sclerotherapy of venous malformations: evaluation of systemic ethanol contamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2916057" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Symptomatic vascular malformations: ethanol embolotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618688" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Advanced management of venous malformation with ethanol sclerotherapy: mid-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11012433" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Serum ethanol levels in children and adults after ethanol embolization or sclerotherapy for vascular anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21822948" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Radio-opaque ethylcellulose-ethanol is a safe and efficient sclerosing agent for venous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14740248" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21629410" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A Step-by-Step Practical Approach to Imaging Diagnosis and Interventional Radiologic Therapy in Vascular Malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26710030" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intralesional Bleomycin Injections for Vascular Malformations: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437659" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Fatal pulmonary fibrosis from low-dose bleomycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9232699" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Percutaneous sclerotherapy of venous malformations of the head and neck using sodium tetradecyl sulphate (sotradecol).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20590708" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sclerosants: a comparative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17377179" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Percutaneous sodium tetradecyl sulfate sclerotherapy for peripheral venous vascular malformations: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22341629" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Sodium tetradecyl sulphate sclerotherapy for treating venous malformations of the oral and pharyngeal regions in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18295109" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prospective randomized efficacy of ultrasound-guided foam sclerotherapy compared with ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21818522" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Percutaneous sclerotherapy of peripheral venous malformations in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14623700" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Treatment of venous malformations with sclerosant in microfoam form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16414404" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Stroke after varicose vein foam injection sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19341886" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Fluoroscopy-guided foam sclerotherapy with sodium morrhuate for peripheral venous malformations: Preliminary experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11860427" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20386776" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The first case of takotsubo cardiomyopathy associated with sodium tetradecyl sulphate sclerotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30855337" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Rapamycin and treatment of venous malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26783326" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27273326" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Response of Blue Rubber Bleb Nevus Syndrome to Sirolimus Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27128161" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Single-center experience with sirolimus therapy for vascular malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30565378" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Sirolimus in blue rubber bleb naevus syndrome: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30373605" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34082006" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A prospective multicenter study of sirolimus for complicated vascular anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34524406" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147000" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
